BIOMARIN PHARMACEUTICAL ($BMRN) posted quarterly earnings results on Monday, August 4th. The company reported earnings of $1.44 per share, beating estimates of $0.85 by $0.59. The company also reported revenue of $825,410,000, beating estimates of $775,175,479 by $50,234,521.
You can see Quiver Quantitative's $BMRN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOMARIN PHARMACEUTICAL Insider Trading Activity
BIOMARIN PHARMACEUTICAL insiders have traded $BMRN stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $BMRN stock by insiders over the last 6 months:
- CHARLES GREG GUYER (EVP, Chief Technical Officer) sold 7,034 shares for an estimated $501,355
- ERIN BURKHART (GVP, Chief Accounting Officer) has made 0 purchases and 3 sales selling 4,425 shares for an estimated $290,448.
- CRISTIN HUBBARD (EVP, Chief Commercial Officer) sold 273 shares for an estimated $17,723
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIOMARIN PHARMACEUTICAL Hedge Fund Activity
We have seen 313 institutional investors add shares of BIOMARIN PHARMACEUTICAL stock to their portfolio, and 258 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 3,841,117 shares (-29.6%) from their portfolio in Q1 2025, for an estimated $271,528,560
- AQR CAPITAL MANAGEMENT LLC added 1,642,206 shares (+127.9%) to their portfolio in Q1 2025, for an estimated $116,087,542
- AVORO CAPITAL ADVISORS LLC removed 1,462,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $103,384,125
- CITADEL ADVISORS LLC added 1,207,445 shares (+311.5%) to their portfolio in Q1 2025, for an estimated $85,354,287
- GOLDMAN SACHS GROUP INC added 1,083,512 shares (+212.7%) to their portfolio in Q1 2025, for an estimated $76,593,463
- BANK OF NEW YORK MELLON CORP removed 1,021,389 shares (-42.6%) from their portfolio in Q1 2025, for an estimated $72,201,988
- VESTAL POINT CAPITAL, LP removed 860,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $60,793,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOMARIN PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 05/05/2025
- Oppenheimer issued a "Outperform" rating on 02/24/2025
- UBS issued a "Buy" rating on 02/20/2025
- Piper Sandler issued a "Overweight" rating on 02/20/2025
- B of A Securities issued a "Buy" rating on 02/20/2025
- Cantor Fitzgerald issued a "Overweight" rating on 02/20/2025
To track analyst ratings and price targets for BIOMARIN PHARMACEUTICAL, check out Quiver Quantitative's $BMRN forecast page.
BIOMARIN PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $BMRN recently. We have seen 11 analysts offer price targets for $BMRN in the last 6 months, with a median target of $98.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $96.0 on 07/22/2025
- Jessica Fye from JP Morgan set a target price of $113.0 on 07/14/2025
- Salveen Richter from Goldman Sachs set a target price of $104.0 on 05/05/2025
- David Lebovitz from Citigroup set a target price of $78.0 on 05/02/2025
- Leland Gershell from Oppenheimer set a target price of $98.0 on 02/24/2025
- George Farmer from Scotiabank set a target price of $80.0 on 02/20/2025
- Luca Issi from RBC Capital set a target price of $70.0 on 02/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
